Inhibition of glial cell activation
Compounds and methods useful for inhibition of glial cell activation and for the treatment of diseases associated with increased glial cell activation in mammalian species including humans are presented.
1 . A method for the inhibition of glial cell activation in a human subject in need thereof comprising administering an effective amount of a compound of Formula 1, or a pharmaceutically acceptable salt, or ester, thereof optionally in association with a pharmaceutically acceptable adjuvant, diluent, or carrier
wherein:
A is selected from 2,3-dihydro-1,4-benzodioxin-6-yl, 1,4-benzodioxin-6-yl, 2,3-dihydro-1,4-benzoxathiin-6-yl, 2,3-dihydro-1,4-benzoxathiin-6-yl, 1,4-benzoxathiin-6-yl, 1,4-benzoxathiin-6-yl, 7-(yl)chroman-4-one, 6-(yl)chroman-4-one, 7-(yl)chromen-4-one, 7-(yl)chromen-4-one, 2,3-dihydrobenzo[g][1,4]benzodioxin-7-yl, benzo[g][1,4]benzodioxin-7-yl, 2,3-dihydrobenzo[g][1,4]benzoxathiin-7-yl, 2,3-dihydrobenzo[g][1,4]benzoxathiin-8-yl, benzo[g][1,4]benzoxathiin-7-yl, benzo[g][1,4]benzoxathiin-8-yl, 8-(yl)2,3-dihydrobenzo[g]chromen-4-one, 7-(yl)2,3-dihydrobenzo[g]chromen-4-one, 8-(yl)benzo[g]chromen-4-one, 7-(yl)benzo[g]chromen-4-one, each of which may be optionally substituted;
D is selected from COCH 2 , COCH 2 CH 2 , COCH 2 CH 2 CH 2 , CH 2 COCH 2 CH 2 , CHOHCH 2 CH 2 , COCHCH, COCH 2 CH(CH 3 ), COCHC(CH 3 ), COCH 2 CO, COSCH 2 CH 2 , COSCOCH 2 , COOCH 2 CH 2 , CONHCH 2 CH 2 , COCH 2 COCH 2 , COCOCH 2 , CHSCOCH 2 , COCOCH 2 CH 2 , SO 2 CH 2 CH 2 , SO 2 CH 2 CH 2 CH 2 , SO 2 CH 2 CH(CH 3 ), SO 2 CHC(CH 3 ), SO 2 CH 2 COCH 2 , CH 2 COCH 2 CH 2 , COC 6 H 4 CH 2 , C 6 H 4 COCH 2 CH 2 , C 6 H 4 COCH 2 , COCH 2 C 6 H 4 , COOCH 2 C 6 H 4 , COSCH 2 C 6 H 4 , COC 5 NH 3 CH 2 , C 5 NH 3 COCH 2 CH 2 , C 5 NH 3 COCH 2 , COCH 2 C 5 NH 3 , COOCH 2 C 5 NH 3 , COSCH 2 C 5 NH 3 , CH 2 NHCOCH 2 CH 2 , CH 2 CH(OH)CH 2 CH 2 ;
n is 1;
R 1 , R 2 , R 3 , and R 4 are independently selected from H, OH, F, Cl, Br, I, (halogen)alkyl, optionally substituted C 1 to C 8 straight chain or branched chain alkyl, optionally substituted C 1 to C 8 cycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, optionally substituted C 1 to C 8 alkenyl, optionally substituted C 1 to C 8 alkynyl, optionally substituted aryl, optionally substituted alkylaryl, optionally substituted heteroaryl, optionally substituted alkylheteroaryl, O-alkyl, O-optionally substituted alkyl, O-cycloalkyl, O-alkylcycloalkyl, O-aryl, O-optionally substituted aryl, alkyl-O-aryl, alkyl-O-optionally substituted aryl, C(O)-aryl, C(O)-optionally substituted aryl, CH 2 C(O)-aryl, CH 2 C(O)-optionally substituted aryl, O-(halogen)alkyl, wherein adjacent substituents R 1 and R 3 , R 2 and R 4 , when present, may form a saturated or unsaturated 5 membered or 6-membered or 7 membered carbocyclic or heterocyclic ring;
wherein alkenyl, if present, may refer to one or more double bond and each double bond may independently be cis or trans, E or Z, a cis/trans mixture or an E/Z mixture and wherein if an asymmetric center is present or asymmetric centers are present the compound may be in the form of a racemic mixture, a single enantiomer, a diastereoisomeric mixture, an enantiomeric diastereomer, a meso compound, a pure epimer, or a mixture of epimers thereof and wherein a hydrogen, several hydrogens or all hydrogens may be replaced with deuterium,
wherein inhibition of glial cell activation treats a treatment of a disease or disorder selected from the group consisting of Alzheimer's disease, Amyotrophic lateral sclerosis, Frontotemporal lobar dementia, Parkinson's disease, Prion diseases, Ataxia, Multiple system atrophy, Corticobasal degeneration, Guillain-Barre syndrome, Lewy body dementia, Multiple sclerosis, Motor neuron disease, Retinopathy, Spinocerebellar ataxia, Huntington's disease, Autism Spectrum Disorder, Attention Deficit Hyperactivity disorder, Fragile X syndrome, Bipolar disorder, Post-Traumatic Stress disorder, Schizophrenia, Diabetic neuropathy, Neuropathic pain, Neuromyelitis Optica spectrum disorder, Post-Traumatic Brain Injury syndrome, and epilepsy.
2 . The method according to claim 1 further comprising administering a second compound selected from the group consisting of Non-steroidal anti-inflammatory drugs, Immunomodulatory agents, Anti-malarial agents, Antibiotics, Anti-TNF alpha agents, Anti-CD20 agents, Anti-compliment factor agents, Anti-diarrheal agents, Anti-depressants, Antipsychotics, Anti-fungal agents, Anti-helminthics, T lymphocyte activation inhibitors, Anti-IL-1 agents, Glucocorticoids, Anti-cytokine/chemokine antibodies, Anti-cytokine/chemokine/nucleic acid or peptide aptamers, Sex steroids and receptor modulators, Anti-cellular surface receptor antibodies directed against cell surface receptors, Anti-cellular surface receptor nucleic acid or peptide aptamers, Aminosalicylic acid derivatives, Anticholinergic agents, Adrenergic agonists, Cholinergic agonists, Corticosteroids, Antineoplastic chemotherapeutic agents, Phosphodiesterase inhibitors, Leukotriene pathway modulators, Monoclonal antibodies directed against human immunoglobulins, Adrenergic antagonists, Calcium channel antagonists, Dopamine agonists, Serotonin agonists, Dopamine antagonists, Serotonin antagonists, Monoamine reuptake inhibitors, Protease inhibitors, Histamine receptor antagonists, Proton pump inhibitors, HMG-COA reductase inhibitors, Retinoids, Histone deacetylase inhibitors, Janus kinase/signal transducer and activator of transcription (JAK/STAT) inhibitors, Angiotensin antagonists, Anti-hyperlipidemics, Anti-hyperglycemic agents, Weight loss agents, Anti-parkinsonism agents, Monoamine oxidase inhibitors, Neurosteroids, Pattern recognition receptor antagonists and inhibitors, and Purinergic receptor antagonists and inhibitors.
3 . A method to simultaneously inhibit the production by glial cells of at least two biomarkers selected from the group consisting of CCL2, CCL5, CXCL10, IL-1beta, IL-6, INF-beta, TNF-alpha, and VEGF, under conditions that produce activation of glial cells, comprising administering to a patient in need thereof an effective amount of a compound of Formula 1, or a pharmaceutically acceptable salt, or ester, thereof optionally in association with a pharmaceutically acceptable adjuvant, diluent, or carrier
wherein:
A is selected from 2,3-dihydro-1,4-benzodioxin-6-yl, 1,4-benzodioxin-6-yl, 2,3-dihydro-1,4-benzoxathiin-6-yl, 2,3-dihydro-1,4-benzoxathiin-6-yl, 1,4-benzoxathiin-6-yl, 1,4-benzoxathiin-6-yl, 7-(yl)chroman-4-one, 6-(yl)chroman-4-one, 7-(yl)chromen-4-one, 7-(yl)chromen-4-one, 2,3-dihydrobenzo[g][1,4]benzodioxin-7-yl, benzo[g][1,4]benzodioxin-7-yl, 2,3-dihydrobenzo[g][1,4]benzoxathiin-7-yl, 2,3-dihydrobenzo[g][1,4]benzoxathiin-8-yl, benzo[g][1,4]benzoxathiin-7-yl, benzo[g][1,4]benzoxathiin-8-yl, 8-(yl)2,3-dihydrobenzo[g]chromen-4-one, 7-(yl)2,3-dihydrobenzo[g]chromen-4-one, 8-(yl)benzo[g]chromen-4-one, 7-(yl)benzo[g]chromen-4-one, each of which may be optionally substituted;
D is selected from COCH 2 , COCH 2 CH 2 , COCH 2 CH 2 CH 2 , CH 2 COCH 2 CH 2 , CHOHCH 2 CH 2 , COCHCH, COCH 2 CH(CH 3 ), COCHC(CH 3 ), COCH 2 CO, COSCH 2 CH 2 , COSCOCH 2 , COOCH 2 CH 2 , CONHCH 2 CH 2 , COCH 2 COCH 2 , COCOCH 2 , CHSCOCH 2 , COCOCH 2 CH 2 , SO 2 CH 2 CH 2 , SO 2 CH 2 CH 2 CH 2 , SO 2 CH 2 CH(CH 3 ), SO 2 CHC(CH 3 ), SO 2 CH 2 COCH 2 , CH 2 COCH 2 CH 2 , COC 6 H 4 CH 2 , C 6 H 4 COCH 2 CH 2 , C 6 H 4 COCH 2 , COCH 2 C 6 H 4 , COOCH 2 C 6 H 4 , COSCH 2 C 6 H 4 , COC 5 NH 3 CH 2 , C 5 NH 3 COCH 2 CH 2 , C 5 NH 3 COCH 2 , COCH 2 C 5 NH 3 , COOCH 2 C 5 NH 3 , COSCH 2 C 5 NH 3 , CH 2 NHCOCH 2 CH 2 , CH 2 CH(OH)CH 2 CH 2 ;
n is 1;
R 1 , R 2 , R 3 , and R 4 are independently selected from H, OH, F, Cl, Br, I, (halogen)alkyl, optionally substituted C 1 to C 8 straight chain or branched chain alkyl, optionally substituted C 1 to C 8 cycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, optionally substituted C 1 to C 8 alkenyl, optionally substituted C 1 to C 8 alkynyl, optionally substituted aryl, optionally substituted alkylaryl, optionally substituted heteroaryl, optionally substituted alkylheteroaryl, O-alkyl, O-optionally substituted alkyl, O-cycloalkyl, O-alkylcycloalkyl, O-aryl, O-optionally substituted aryl, alkyl-O-aryl, alkyl-O-optionally substituted aryl, C(O)-aryl, C(O)-optionally substituted aryl, CH 2 C(O)-aryl, CH 2 C(O)-optionally substituted aryl, O-(halogen)alkyl, wherein adjacent substituents R 1 and R 3 , R 2 and R 4 , when present, may form a saturated or unsaturated 5 membered or 6-membered or 7 membered carbocyclic or heterocyclic ring;
wherein alkenyl, if present, may refer to one or more double bond and each double bond may independently be cis or trans, E or Z, a cis/trans mixture or an E/Z mixture and wherein if an asymmetric center is present or asymmetric centers are present the compound may be in the form of a racemic mixture, a single enantiomer, a diastereoisomeric mixture, an enantiomeric diastereomer, a meso compound, a pure epimer, or a mixture of epimers thereof and wherein a hydrogen, several hydrogens or all hydrogens may be replaced with deuterium.
4 . The method according to claim 3 , wherein production of biomarkers CCL2, IL-1beta, IL-6, TNF-alpha and VEGF are simultaneously inhibited.
5 . The method according to claim 3 , wherein production of biomarkers CCL5, CXCL10, INF-beta, and TNF-alpha are simultaneously inhibited.
6 . The method according to claim 3 , wherein production of biomarkers CCL2, IL-6, and TNF-alpha are simultaneously inhibited.
7 . The method according to claim 1 , wherein the compound is selected from compounds 1-30, compounds 31-60, compounds 61-90, compounds 91-120, compounds 121-144, compounds 145-168, compounds 169-192, compounds 193-217, compounds 218-240, or compounds 241-264.
8 . The method according to claim 1 , wherein the compound is selected from compounds 265-288, compounds 289-312, compounds 313-336, compounds 337-360, compounds 361-384, compounds 385-408, compounds 409-437, compounds 438-465, compounds 466-494, or compounds 495-521.
9 . A compound according to Formula 1
wherein:
A is selected from 2,3-dihydro-1,4-benzodioxin-6-yl, 1,4-benzodioxin-6-yl, 2,3-dihydro-1,4-benzoxathiin-6-yl, 2,3-dihydro-1,4-benzoxathiin-6-yl, 1,4-benzoxathiin-6-yl, 1,4-benzoxathiin-6-yl, 7-(yl) chroman-4-one, 6-(yl) chroman-4-one, 7-(yl) chromen-4-one, 7-(yl) chromen-4-one, 2,3-dihydrobenzo [g][1,4]benzodioxin-7-yl, benzo [g][1,4]benzodioxin-7-yl, 2,3-dihydrobenzo [g][1,4]benzoxathiin-7-yl, 2,3-dihydrobenzo [g][1,4]benzoxathiin-8-yl, benzo [g][1,4]benzoxathiin-7-yl, benzo [g][1,4]benzoxathiin-8-yl, 8-(yl) 2,3-dihydrobenzo [g]chromen-4-one, 7-(yl) 2,3-dihydrobenzo [g]chromen-4-one, 8-(yl) benzo [g]chromen-4-one, 7-(yl) benzo [g]chromen-4-one, each of which may be optionally substituted;
D is selected from COCH 2 , COCH 2 CH 2 , COCH 2 CH 2 CH 2 , CH 2 COCH 2 CH 2 , CHOHCH 2 CH 2 , COCHCH, COCH 2 CH(CH 3 ), COCHC(CH 3 ), COCH 2 CO, COSCH 2 CH 2 , COSCOCH 2 , COOCH 2 CH 2 , CONHCH 2 CH 2 , COCH 2 COCH 2 , COCOCH 2 , CHSCOCH 2 , COCOCH 2 CH 2 , SO 2 CH 2 CH 2 , SO 2 CH 2 CH 2 CH 2 , SO 2 CH 2 CH(CH 3 ), SO 2 CHC(CH 3 ), SO 2 CH 2 COCH 2 , CH 2 COCH 2 CH 2 , COC 6 H 4 CH 2 , C 6 H 4 COCH 2 CH 2 , C 6 H 4 COCH 2 , COCH 2 C 6 H 4 , COOCH 2 C 6 H 4 , COSCH 2 C 6 H 4 , COC 5 NH 3 CH 2 , C 5 NH 3 COCH 2 CH 2 , C 5 NH 3 COCH 2 , COCH 2 C 5 NH 3 , COOCH 2 C 5 NH 3 , COSCH 2 C 5 NH 3 , CH 2 NHCOCH 2 CH 2 , CH 2 CH(OH) CH 2 CH 2 ;
nis 1;
R 1 , R 2 , R 3 , and R 4 are independently selected from H, OH, F, CI, Br, I, (halogen)alkyl, optionally substituted C 1 to C 8 straight chain or branched chain alkyl, optionally substituted C 1 to C 8 cycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, optionally substituted C 1 to C 8 alkenyl, optionally substituted C 1 to C 8 alkynyl, optionally substituted aryl, optionally substituted alkylaryl, optionally substituted heteroaryl, optionally substituted alkylheteroaryl, O-alkyl, O-optionally substituted alkyl, O-cycloalkyl, O-alkylcycloalkyl, O-aryl, O-optionally substituted aryl, alkyl-O-aryl, alkyl-O-optionally substituted aryl, C(O)-aryl, C(O)-optionally substituted aryl, CH 2 C(O)-aryl, CH 2 C(O)-optionally substituted aryl, O-(halogen) alkyl, wherein adjacent substituents R 1 and R 3 , R 2 and R 4 , when present, may form a saturated or unsaturated 5 membered or 6-membered or 7 membered carbocyclic or heterocyclic ring;
wherein alkenyl, if present, may refer to one or more double bond and each double bond may independently be cis or trans, E or Z, a cis/trans mixture or an E/Z mixture and wherein if an asymmetric center is present or asymmetric centers are present the compound may be in the form of a racemic mixture, a single enantiomer, a diastereoisomeric mixture, an enantiomeric diastereomer, a meso compound, a pure epimer, or a mixture of epimers thereof and wherein a hydrogen, several hydrogens or all hydrogens may be replaced with deuterium,
wherein the compound is selected from compounds 2-521;
or a pharmaceutically acceptable salt, or ester thereof.
10 . A pharmaceutical composition comprising a compound according to claim 9 and a pharmaceutically acceptable adjuvant, diluent, and/or carrier.
11 . The pharmaceutical composition according to claim 10 in the form of a tablet, capsule, granule, powder, gel, caplet, troche, sachet, cachet, pouch, gum, sprinkle, liquid solution, suspension, or buccal and gastro-retentive preparation.
12 . A pharmaceutical composition combination comprising a therapeutically effective amount of a composition comprising:
(a) a first compound according to claim 9 ; and
(b) a second compound selected from the group consisting of Non-steroidal anti-inflammatory drugs, Immunomodulatory agents, Anti-malarial agents, Antibiotics, Anti-TNF alpha agents, Anti-CD20 agents, Anti-compliment factor agents, Anti-diarrheal agents, Anti-depressants, Antipsychotics, Anti-fungal agents, Anti-helminthics, T lymphocyte activation inhibitors, Anti-IL-1 agents, Glucocorticoids, Anti-cytokine/chemokine antibodies, Anti-cytokine/chemokine/nucleic acid or peptide aptamers, Sex steroids and receptor modulators, Anti-cellular surface receptor antibodies directed against cell surface receptors, Anti-cellular surface receptor nucleic acid or peptide aptamers, Aminosalicylic acid derivatives, Anticholinergic agents, Adrenergic agonists, Cholinergic agonists, Corticosteroids, Antineoplastic chemotherapeutic agents, Phosphodiesterase inhibitors, Leukotriene pathway modulators, Monoclonal antibodies directed against human immunoglobulins, Adrenergic antagonists, Calcium channel antagonists, Dopamine agonists, Serotonin agonists, Dopamine antagonists, Serotonin antagonists, Monoamine reuptake inhibitors, Protease inhibitors, Histamine receptor antagonists, Proton pump inhibitors, HMG-CoA reductase inhibitors, Retinoids, Histone deacetylase inhibitors, Janus kinase/signal transducer and activator of transcription (JAK/STAT) inhibitors, Angiotensin antagonists, Anti-hyperlipidemics, Anti-hyperglycemic agents, Weight loss agents, Anti-parkinsonism agents, Monoamine oxidase inhibitors, Neurosteroids, Pattern recognition receptor antagonists and inhibitors, and Purinergic receptor antagonists and inhibitors.
13 . The pharmaceutical composition combination according to claim 12 in the form of a tablet, capsule, granule, powder, gel, caplet, troche, sachet, cachet, pouch, gum, sprinkle, liquid solution, suspension, or buccal and gastro-retentive preparation.